The acquisition also advances Lantheus’ capabilities with the addition of Evergreen’s radioligand therapy manufacturing infrastructure, including a revenue-generating CDMO business.

Analysts raise price forecasts. Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio Lantheus strengthens its radiopharmaceutical ...

The acquisition also advances Lantheus’ capabilities with the addition of Evergreen’s radioligand therapy manufacturing infrastructure, including a revenue-generating CDMO business. “Today marks a ...

Lantheus (LNTH) Holdings announced that it has completed its previously announced acquisition of Evergreen Theragnostics, a clinical-stage radiopharmaceutical company. The acquisition was first ...